Basal Insulin (Long-acting Insulin) Market

• In March 2023: Novo Nordisk announced that the company will drop prices for vials and pens of NovoLog and other insulin brands by 75 percent beginning January 1, 2024, in the United States. The price for some other Novo Nordisk insulin brands will be lowered by 65 percent.
• In October 2022: Novo Nordisk announced headline results from the ONWARDS 5 phase 3a trial with once-weekly insulin icodec in people with type 2 diabetes. The ONWARDS 5 trial was a 52-week, open-label efficacy and safety treat-to-target trial investigating once-weekly insulin versus once-daily basal insulin (insulin degludec or insulin glargine U100/U300).

In this report, the basal insulin (long-acting insulin) market has been segmented by Product, Application, Distribution Channel and Geography.

Basal Insulin (Long-acting Insulin) Market, Segmentation by Product

The Basal Insulin (Long-acting Insulin) Market has been segmented by Product into Lantus, Levemir, Toujeo, Tresiba, Basaglar and Insulin Glargine Biosimilars and Basal or Long-acting Insulins.

Lantus

Lantus remains one of the leading products in the basal insulin market, capturing approximately 35% of the global share. Known for its stable and long-lasting effect, Lantus is widely prescribed for diabetes management worldwide. Its strong brand presence and extensive clinical data support its continued dominance.

Levemir

Levemir holds about 25% of the market, appreciated for its flexibility in dosing and reduced risk of hypoglycemia. This insulin product is favored by both patients and healthcare providers for its predictable action and effectiveness in controlling blood sugar levels over 24 hours.

Toujeo

Toujeo, a concentrated form of insulin glargine, accounts for nearly 15% of the market share. Its higher concentration allows for smaller injection volumes, enhancing patient comfort and adherence. Toujeo is gaining traction among patients needing higher insulin doses.

Tresiba

Tresiba represents around 15% of the basal insulin market, recognized for its ultra-long-acting profile and flexibility in dosing time. It offers improved glycemic control and reduced risk of nocturnal hypoglycemia, making it popular among patients with fluctuating blood sugar levels.

Basaglar

Basaglar, an insulin glargine biosimilar, comprises roughly 7% of the market. As a cost-effective alternative to branded insulins, Basaglar is helping expand access to basal insulin therapies, especially in price-sensitive markets. Its growing adoption is supported by increasing awareness of biosimilars.

Insulin Glargine Biosimilars

Other insulin glargine biosimilars collectively contribute about 8% to the market. These biosimilars offer comparable efficacy and safety to originator products at reduced costs, driving competition and accessibility in the basal insulin market globally.

Basal Insulin (Long-acting Insulin) Market, Segmentation by Application

The Basal Insulin (Long-acting Insulin) Market has been segmented by Application into Type 1 Diabetes, Type 2 Diabetes.

Type 1 Diabetes

The basal insulin market caters significantly to patients with Type 1 Diabetes, representing approximately 40% of the market share. Individuals with Type 1 Diabetes require long-acting insulin to manage their condition effectively, as their bodies do not produce insulin naturally. The use of basal insulin in this segment helps maintain steady blood glucose levels and prevents hyperglycemia throughout the day and night.

Type 2 Diabetes

Type 2 Diabetes accounts for nearly 60% of the basal insulin market, driven by the growing prevalence of this condition globally. Patients with Type 2 Diabetes often experience insulin resistance and benefit from basal insulin to complement oral medications or other treatments. The increasing adoption of basal insulin in Type 2 Diabetes management supports better glycemic control and reduces the risk of complications.

Basal Insulin (Long-acting Insulin) Market, Segmentation by Distribution Channel

The Basal Insulin (Long-acting Insulin) Market has been segmented by Distribution Channel into Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies.

Hospital Pharmacies

Hospital pharmacies represent a significant portion of the basal insulin distribution market, accounting for about 45% of sales. These pharmacies play a crucial role in delivering basal insulin to patients, especially those admitted for diabetes management or post-surgical care. The availability of basal insulin in hospital settings ensures timely and supervised administration, crucial for patients requiring immediate or intensive treatment.

Retail Pharmacies

Retail pharmacies dominate the distribution channel with nearly 40% market share, providing easy access to basal insulin for outpatients. They serve as convenient points for patients to refill prescriptions and receive counseling on proper insulin use. The widespread presence of retail pharmacies across urban and rural areas supports continuous treatment adherence and enhances patient convenience.

Online Pharmacies

Online pharmacies are rapidly emerging in the basal insulin market, holding around 15% of the distribution channel share. The growing preference for digital health solutions and home delivery services is driving this segment’s expansion. Online pharmacies offer discreet, accessible and often cost-effective options for patients to obtain basal insulin, especially in remote regions or during pandemic-related restrictions.

Basal Insulin (Long-acting Insulin) Market, Segmentation by Geography

In this report, the Basal Insulin (Long-acting Insulin) Market has been segmented by Geography into five regions; North America, Europe, Asia Pacific, Middle East & Africa and Latin America.

Basal Insulin (Long-acting Insulin) Market Share (%), by Geographical Region.

North America

North America holds a significant share in the basal insulin market, accounting for around 40% of the global revenue. The region benefits from advanced healthcare infrastructure and widespread adoption of long-acting insulin therapies among diabetic patients. Increasing prevalence of diabetes and growing awareness contribute to steady market growth.

Europe

Europe represents approximately 30% of the basal insulin market. The region is characterized by strong government initiatives promoting diabetes care and reimbursement policies that support insulin accessibility. Adoption of innovative insulin delivery systems also drives market expansion across European countries.

Asia Pacific

The Asia Pacific market is rapidly expanding, contributing nearly 20% to the global share. Rising diabetes incidence, improved healthcare facilities and increasing patient awareness are key factors fueling growth. Emerging economies like China and India are expected to drive substantial demand in this region.

Middle East & Africa

This region accounts for about 5% of the basal insulin market. Limited healthcare infrastructure in some areas is offset by growing investments and increasing prevalence of diabetes. Market growth is supported by initiatives to improve diabetes diagnosis and treatment accessibility.

Latin America

Latin America holds around 5% of the market share, with increasing diabetes cases fueling demand for basal insulin. Growing healthcare expenditure and government programs aimed at improving chronic disease management further support market growth in this region.

This report provides an in depth analysis of various factors that impact the dynamics of Global Basal Insulin (Long-acting Insulin) Market. These factors include; Market Drivers, Restraints and Opportunities Analysis.

Drivers, Restraints and Opportunity Analysis

Drivers:

• Rising prevalence of diabetes
• Increasing adoption of insulin therapy
• Technological advancements in insulin analogs

• Aging population contributing to diabetes incidence - The aging population is significantly contributing to the rising incidence of diabetes globally, reshaping healthcare priorities and emphasizing the need for effective disease management strategies. As individuals age, they become more susceptible to developing type 2 diabetes due to several interconnected factors.

  Aging is associated with physiological changes that affect glucose metabolism. Cells may become less responsive to insulin, leading to insulin resistance, a hallmark of type 2 diabetes. This resistance necessitates higher insulin production by the pancreas to maintain normal blood sugar levels, eventually straining the pancreas and potentially leading to diabetes.

  Lifestyle factors such as sedentary behavior and poor diet often become more prevalent with age, exacerbating the risk of developing diabetes. Reduced physical activity and increased body weight are common among older adults, further contributing to insulin resistance and the onset of diabetes.

  Aging is frequently accompanied by comorbidities such as hypertension, cardiovascular disease and obesity, which are all interconnected with diabetes. These conditions can create a complex web of health challenges, requiring comprehensive management strategies to mitigate the risk of diabetes complications.

Restraints:

• High cost of insulin therapy
• Regulatory challenges in approval processes
• Limited access to healthcare in some regions

• Concerns over hypoglycemia and weight gain - Concerns over hypoglycemia and weight gain are significant considerations in the management of diabetes, particularly for individuals using insulin therapies, including basal insulins.

  Hypoglycemia, or low blood sugar levels, is a critical concern associated with insulin therapy. It occurs when blood glucose levels drop below normal levels (typically below 70 mg/dL), leading to symptoms such as shakiness, confusion, dizziness, sweating and in severe cases, loss of consciousness or seizures. Hypoglycemia can occur when insulin doses are too high relative to food intake or physical activity, or when there are delays or omissions in meals or snacks. Elderly patients and those with impaired kidney function are particularly vulnerable to hypoglycemia. Fear of hypoglycemia can also lead to patients intentionally running higher blood glucose levels, which can have negative long-term health consequences.

  Weight gain is another common concern associated with insulin therapy, including basal insulins. Insulin promotes glucose uptake into cells, which can lead to increased fat storage and weight gain, especially if insulin doses are not optimized or if there are concurrent lifestyle factors such as overeating or reduced physical activity. Weight gain can exacerbate insulin resistance and complicate diabetes management efforts, potentially leading to higher insulin requirements over time.

  Healthcare providers strive to create personalized treatment plans that balance blood glucose control with minimizing the risk of hypoglycemia. This may involve adjusting insulin doses based on lifestyle factors, monitoring blood glucose levels regularly and educating patients on recognizing and managing hypoglycemia.

  CGM systems provide real-time glucose readings, allowing patients and healthcare providers to monitor trends and make timely adjustments to insulin therapy. This technology helps reduce the incidence of hypoglycemia by providing early warnings of impending low blood sugar levels.

  Advances in insulin delivery systems, such as insulin pens and insulin pumps, offer options for precise insulin administration, which can help minimize fluctuations in blood glucose levels and reduce the risk of hypoglycemia.

Opportunities:

• High cost of insulin therapy
• Regulatory challenges in approval processes
• Limited access to healthcare in some regions

• Concerns over hypoglycemia and weight gain - Concerns over hypoglycemia and weight gain are critical considerations in the management of diabetes, particularly among individuals who require insulin therapy, including basal insulins.

  Hypoglycemia occurs when blood glucose levels drop below normal (typically below 70 mg/dL), leading to symptoms such as shakiness, confusion, sweating and in severe cases, loss of consciousness or seizures. It is a common side effect of insulin therapy, especially if insulin doses are too high relative to food intake or physical activity levels. Fear of hypoglycemia can lead individuals to avoid insulin doses or reduce carbohydrate intake, which can worsen diabetes control over time. Continuous glucose monitoring (CGM) systems and educating patients on recognizing and managing hypoglycemia are crucial to minimizing its occurrence.

  Weight gain can occur with insulin therapy due to its role in promoting glucose uptake into cells, which can lead to increased fat storage. This weight gain is more likely if insulin doses are not carefully adjusted or if individuals consume excess calories without adjusting their insulin regimen. Weight gain can exacerbate insulin resistance and complicate diabetes management efforts. Encouraging a balanced diet, regular physical activity and considering insulin formulations that may have a lower propensity for weight gain are strategies to mitigate this risk.

  Managing diabetes with insulin therapy involves a delicate balance between achieving optimal blood glucose control while minimizing the risks of hypoglycemia and weight gain. Healthcare providers play a crucial role in educating patients about these risks, optimizing insulin dosing based on individual needs and providing ongoing support to help patients achieve and maintain their treatment goals.

Key players in Global Basal Insulin (Long-acting Insulin) Market include:

• Novo Nordisk
• Sanofi
• Eli Lilly
• Biocon
• Julphar

In this report, the profile of each market player provides following information:

• Company Overview and Product Portfolio
• Key Developments
• Financial Overview
• Strategies
• Company SWOT Analysis